revnock.

You’re previewing Everwell Concierge — a sample business built on RevNock. Everything here works.

Start with 45 days freeOwner’s view
Owner’s view:Market intelligence Start with 45 days free Starting at $3,000/month
Back to the journalEverwell Concierge journal / A clearer conversation about feeling well

Bioidentical is not an evidence shortcut

Menopause choices, preventive care and care coordination, explained with evidence.

THE DEVELOPMENT

ACOG recommends FDA-approved hormone therapy over compounded hormone products.

Source for this context: ACOG: hormone therapy for menopause

What this changes.

WHAT WE DO ABOUT IT

We explain formulation, approval and indication in plain language instead of hiding behind a single lifestyle label.

Our reading of the reference above. Whether a product or device suits you is decided in consultation.

The approaches behind the conversation.

Each reference below has its own mechanism, scope and official source, so we never treat them as interchangeable.

ACOG / Individualized assessment

Menopause care has more than one route

Systemic and local hormone therapies address different symptoms. The decision includes the uterus, health history, treatment route, risks and nonhormonal alternatives.

  • Separate hot flashes from local vaginal or urinary symptoms.
  • Ask when progestogen is needed with systemic estrogen.
  • Discuss follow-up and reasons to reconsider the plan.

Official reference: ACOG: hormone therapy for menopause

CombiPatch / Transdermal therapy

The route is part of the prescription

CombiPatch combines estradiol with the progestin norethindrone acetate in a prescription patch. Formulation and route are specific clinical choices, not interchangeable wellness accessories.

  • Discuss the indication and full prescribing safety information.
  • Compare combined patches with other clinician-selected regimens.
  • Review skin tolerance, bleeding questions and reassessment.

Official reference: CombiPatch: estradiol and norethindrone acetate prescribing information

Astellas / VEOZAH

A nonhormonal hot-flash conversation

VEOZAH is a fezolinetant prescription option for moderate-to-severe vasomotor symptoms due to menopause. It has important liver-safety and monitoring requirements.

  • Review liver history and interacting medicines.
  • Ask about the required blood-test schedule.
  • Compare the option with hormone therapy and other approaches.

Official reference: Astellas: VEOZAH information and liver monitoring

BRING YOUR OWN PRIORITIES

Questions for the next conversation.

  1. Menopause consultation: What should an individual assessment clarify before I consider menopause consultation? Read the service guide
  2. Hormone symptom assessment: What should an individual assessment clarify before I consider hormone symptom assessment? Read the service guide
  3. Preventive health review: What should an individual assessment clarify before I consider preventive health review? Read the service guide
THE SOURCE NOTEBOOK

Read the original references.

References reviewed . Linked manufacturers and professional bodies have not reviewed or endorsed this article.

  1. ACOG: hormone therapy for menopause
  2. CombiPatch: estradiol and norethindrone acetate prescribing information
  3. Astellas: VEOZAH information and liver monitoring

Manufacturer and product names belong to their owners and link to official information. No affiliation or authorized-provider status is implied.

General information, not medical advice.

More from the journal

Keep reading.